Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal hematopoietic stem cell disease characterized by acquired abnormalities in the phosphatidylinositol glycan class A () gene.
Methods: This study analyzed gene using polymerase chain reaction (PCR) followed by Sanger sequencing of 31 Brazilian patients with PNH, including 23 with classical PNH and 8 with subclinical PNH (aplastic anemia and a PNH clone).
Results: A diverse spectrum of acquired variants was identified, encompassing insertions, deletions, and single-base substitutions. The majority of variants identified (17 out of 29) were deemed likely pathogenic for paroxysmal nocturnal hemoglobinuria (PNH). Six variants have undetermined significance (VUS) and six variants are probably benign. Somatic variants exhibited variability in type and location among the patients, with a predominance of small deletions and simple base changes. Notably, 41% of the variants were frameshift and 35% were missense. Among the 23 patients with hemolytic PNH, 19 had at least one detectable pathogenic variant. Subclinical PNH cases were characterized solely by polymorphisms.
Conclusion: In conclusion, the somatic variants in Brazilian PNH patients displayed variability in both site distribution and type. Contrary to mutational hotspots observed in previous studies, none were identified in this cohort. No specific correlation between the clinical characteristics of hemolytic PNH patients and their variants was found, likely due to the extensive variety of mutations.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11891177 | PMC |
http://dx.doi.org/10.3389/fmed.2025.1472186 | DOI Listing |
Front Med (Lausanne)
February 2025
Department of Hematology, Universidade Federal de São Paulo/Escola Paulista de Medicina, São Paulo, Brazil.
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal hematopoietic stem cell disease characterized by acquired abnormalities in the phosphatidylinositol glycan class A () gene.
Methods: This study analyzed gene using polymerase chain reaction (PCR) followed by Sanger sequencing of 31 Brazilian patients with PNH, including 23 with classical PNH and 8 with subclinical PNH (aplastic anemia and a PNH clone).
Results: A diverse spectrum of acquired variants was identified, encompassing insertions, deletions, and single-base substitutions.
Zhonghua Xue Ye Xue Za Zhi
January 2025
National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China.
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal hematologic disorder. Historically, most PNH patients mainly received supportive treatment, which led to poor quality of life and high mortality rates. The advent of downstream complement C5 inhibitors has dramatically changed the natural course of PNH.
View Article and Find Full Text PDFGastroenterology
March 2025
Department of Gastroenterology, West China Hospital, Sichuan University, Sichuan Province, China. Electronic address:
MMW Fortschr Med
March 2025
Klinik für Kardiologie und Angiologie, Medizinische Hochschule Hannover, Hannover, Deutschland.
Pediatr Blood Cancer
March 2025
BC Children's Hospital, Vancouver, British Columbia, Canada.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!